Boehringer In­gel­heim kicks off €350M R&D cen­ter in Ger­many

In line with its ex­pec­ta­tions of snag­ging about 20 new drug ap­provals over the next sev­en years, to­day Boehringer In­gel­heim in­au­gu­rat­ed a new Ger­many-based re­search cen­ter, in­to which the com­pa­ny in­vest­ed €350 mil­lion (more than $386.5 mil­lion).

The Bi­o­log­i­cals De­vel­op­ment Cen­ter, sit­u­at­ed on Boehringer’s cam­pus in Bib­er­ach, will strength­en its bio­phar­ma­ceu­ti­cals de­vel­op­ment, which ac­counts for about 50% of the com­pa­ny’s R&D pipeline. The cen­ter is the largest sin­gle in­vest­ment in Ger­many from the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER